Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Statins

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    207 result(s) found for: Statins. Displaying page 7 of 11.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    EudraCT Number: 2021-005171-40 Sponsor Protocol Number: 1366-0029 Start Date*: 2022-06-20
    Sponsor Name:Boehringer Ingelheim SComm
    Full Title: Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients wi...
    Medical condition: portal hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10036200 Portal hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned) FR (Trial now transitioned) DE (Ongoing) AT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006069-39 Sponsor Protocol Number: LPS16141 Start Date*: 2022-06-26
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Randomized, Double-Blind, Parallel-Group Clinical Trial to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care Versus Placebo Added to Standard of Care, in Non-Alcoho...
    Medical condition: Non-alcoholic fatty liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004871 10082249 Nonalcoholic fatty liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004084-39 Sponsor Protocol Number: 1002-048 Start Date*: 2017-04-19
    Sponsor Name:Esperion Therapeutics Inc.,
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg/day as Add-on to Ezetimibe Therapy in Patie...
    Medical condition: This study is to assess the efficacy of bempedoic acid 180 mg/day versus placebo in decreasing low-density lipoprotein cholesterol (LDL-C) when added to ezetimibe therapy in patients with high LDL-...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10007541 - Cardiac disorders 10007648 Cardiovascular disease, unspecified LLT
    19.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003008-30 Sponsor Protocol Number: 16/0730 Start Date*: 2020-07-01
    Sponsor Name:University College London
    Full Title: A double-blind, randomised, placebo-controlled single-site study of high dose simvastatin treatment for secondary progressive multiple sclerosis: impact on vascular perfusion and oxidative damage
    Medical condition: Multiple Sclerosis (Secondary Progressive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-003376-49 Sponsor Protocol Number: MDCO-PCS-16-02 Start Date*: 2017-06-20
    Sponsor Name:The Medicines Company
    Full Title: An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects with Homozygous Familial Hypercholesterolemia
    Medical condition: Homozygous Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002483-11 Sponsor Protocol Number: 18HH4626 Start Date*: 2019-05-15
    Sponsor Name:Imperial College London
    Full Title: CHOlesterol Reduction with Evolocumab and coronAry microvascuLar function: The CHORAL Flow Study
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10005422 Blood cholesterol PT
    21.1 10022891 - Investigations 10002434 Angiogram coronary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-000465-37 Sponsor Protocol Number: 0524A-082 Start Date*: 2008-05-30
    Sponsor Name:Laboratoires Merck Sharp & Dohme - Chibret
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Ther...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000191-41 Sponsor Protocol Number: GC28210 Start Date*: 2012-06-19
    Sponsor Name:GENENTECH, Inc.
    Full Title: A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF MPSK3169A IN PATIENTS WITH CORONARY HEART DISEASE OR HIGH RISK OF CORONARY HEART DISEASE
    Medical condition: Coronary Heart Disease or High Risk of Coronary Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-004372-20 Sponsor Protocol Number: 1.1(UK) Start Date*: 2006-01-04
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: A randomised, prospective,open-label, multi-centre study comparing the efficacy and safety of conversion to Sirolimus in stable renal transplant recipients with a cutaneous squamous cell carcinoma.
    Medical condition: Cutaneous squamous cell carcinoma after kidney transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003257-42 Sponsor Protocol Number: ACH-CYT-02 Start Date*: 2017-10-03
    Sponsor Name:Achieve Life Sciences Inc
    Full Title: Repeat-Dose Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers
    Medical condition: Smoking cessation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002978-30 Sponsor Protocol Number: KG2104940 Start Date*: 2005-11-28
    Sponsor Name:GlaxoSmithKlin Research and Development Ltd
    Full Title: A double-blind, randomized, placebo-controlled, repeat dose study to compare the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK189075 with GW869682 in subjects with type 2 diabe...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003601 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005757-30 Sponsor Protocol Number: MIRACL IN CABG Start Date*: 2007-07-30
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: MIRACL IN CABG - Statins in cardiac surgery. Effect of doses on inflammatory response and early results
    Medical condition: Pts with coronary disease undergoing coronary artery bypass graft surgery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028600 Myocardial ischaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010163-16 Sponsor Protocol Number: 08/0285 Start Date*: 2009-06-05
    Sponsor Name:University College London
    Full Title: Bile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease
    Medical condition: Active Crohn's disease affecting the ileum
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011406 Crohn's ileitis LLT
    9.1 10058815 Crohn's disease acute episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000055-13 Sponsor Protocol Number: M41008-1102 Start Date*: 2012-12-10
    Sponsor Name:Almirall S.A.
    Full Title: A multi-center, randomized, double-blind, three-arm, 16 week, adaptive phase III clinical study to investigate the efficacy and safety of LAS41008 vs LASW1835 and vs Placebo in patients with moder...
    Medical condition: moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10071117 Plaque psoriasis LLT
    17.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004636-52 Sponsor Protocol Number: 2005AN005 Start Date*: 2006-02-20
    Sponsor Name:Heart of England NHS Foundation Trust
    Full Title: Randomised Double-Blind Placebo Controlled Trial of 40mg/day of Atorvastatin on Reduction in Severity of Sepsis in Ward Patients
    Medical condition: Sepsis is the clinical syndrome defined by the presence of both infection and a systemic inflammatory response. Sepsis is common in general medical and surgical wards with an estimated prevalence ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-003449-15 Sponsor Protocol Number: 301012-CS5 Start Date*: 2007-07-12
    Sponsor Name:Genzyme Europe B.V.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects
    Medical condition: Reduction of low density lipoprotein C (LDL-C) in Homozygous Familial Hypercholesterolemia (HoFH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057080 Homozygous familial hypercholesterolemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004556-30 Sponsor Protocol Number: LPS15021 Start Date*: 2018-08-24
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: A Multicenter, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of a New Formulation of Zenon (Ezetimibe/Rosuvastatin Fixed Dose Combination) in Patien...
    Medical condition: Patients with Primary Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002205-38 Sponsor Protocol Number: 747-207 Start Date*: 2015-12-02
    Sponsor Name:INTERCEPT PHARMACEUTICALS INC.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled,Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects with Primary Sclerosing Cholangitis
    Medical condition: Primary Sclerosing Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005786-11 Sponsor Protocol Number: GS-ES-164-0154 Start Date*: 2006-03-28
    Sponsor Name:Gilead Sciences S.L.
    Full Title: Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from AZT containing backbone to Truvada in HIV-1...
    Medical condition: Human Immunodeficiency Virus (HIV-1) infection
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020161 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-000030-35 Sponsor Protocol Number: RIMINI-Pilot Start Date*: 2013-05-08
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Reduction of Ischemic Myocardium with Ranolazine-Treatment in patients with acute myocardial Ischemia – RIMINI-Pilot-Trial
    Medical condition: CAD with acute ischemia and myocardial dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10028600 Myocardial ischaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 19 10:06:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA